Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation

Rotem Erez, Sharon Ebner, Bernard Attali, Doron Shabat

Research output: Contribution to journalArticlepeer-review


Osseous tissues are considered to be limited as therapeutic target sites due to their biological properties. We have designed and synthesized two kinds of hydrolytically activated chemotherapeutic prodrugs containing bisphosphonate, a bone-targeting moiety. The first can be conjugated to drug molecules with an available hydroxy group; the drug is attached to the bisphosphonate component through an ester-labile linkage. The second is for use with drug molecules with amine functional group. In this case, a self-immolative linker is used to attach the drug to the bisphosphonate component through a carbonate-labile linkage. The concept was demonstrated using the drugs camptothecin, which has a hydroxy functional group, and tryptophan, which is a model molecule for a drug with amine functionality. Both prodrugs showed significant binding capability to hydroxyapatite, the major component of bone, and were hydrolytically activated under physiological conditions.

Original languageEnglish
Pages (from-to)816-820
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Issue number2
StatePublished - 15 Jan 2008


  • Bisphosphonate
  • Bone targeting
  • Cancer
  • Prodrug


Dive into the research topics of 'Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation'. Together they form a unique fingerprint.

Cite this